Volume 14 Supplement 1
Edited by Ulrich Costabel
This supplement originates from presentations given at the symposium AIR: Advancing IPF Research. Working together to translate IPF research into practice held in Berlin in November 2011. The publication was supported by IntraMed Communications with funding from InterMune, AG. The content was proposed by IntraMed Communications and developed with the journal. All articles in the supplement have undergone the journal's standard peer review process.
AIR: Advancing IPF Research. Working together to translate IPF research into practice.
Berlin, Germany4-5 November 2011
Idiopathic pulmonary fibrosis (IPF), the most prevalent idiopathic interstitial pneumonia, is associated with a poor prognosis. An accurate diagnosis of IPF is essential for optimal management. The recent ATS/...
High-resolution computed tomography (HRCT) imaging has a central role in the diagnosis of interstitial lung diseases, particularly in the evaluation of patients with suspected idiopathic pulmonary fibrosis (IP...
The magnitude of treatment effect can be assessed by a number of methods. One reliable method of collectively analysing data from randomised clinical trials is that used in Cochrane reviews. These systematic r...
Idiopathic pulmonary fibrosis (IPF) is a progressive disease, with a median survival time of 2–5 years. The search for effective treatment has involved numerous clinical trials of investigational agents withou...
Patient management in Idiopathic Pulmonary Fibrosis (IPF) is largely based on societal guidelines and recommendations. A recent update by the American Thoracic Society (ATS), European Respiratory Society (ERS)...
Despite receiving ‘weak no’ recommendations in the updated guidelines on treating patients with Idiopathic Pulmonary Fibrosis (IPF), two key treatment options are pirfenidone and N-acetylcysteine (NAC), and bo...
Citation Impact 2023
Journal Impact Factor: 4.7
5-year Journal Impact Factor: 5.3
Source Normalized Impact per Paper (SNIP): 1.192
SCImago Journal Rank (SJR): 1.498
Speed 2023
Submission to first editorial decision (median days): 3
Submission to acceptance (median days): 105
Usage 2023
Downloads: 2,949,876
Altmetric mentions: 2,397